Novo Nordisk is expanding the company's affordability offering in the US beginning January 2, 2020. People with diabetes experience different issues and complexities that can't be covered by one solution. That's why the company continues to bring forth programs that will directly benefit even more people with diabetes – including those with insurance and those without – as we work toward much needed longer-term systemic reform. 

Expanded affordability options available on January 2, 2020

The new offerings will include:

• $99.00 Cash Card Program for Analog Insulins: Allows people with diabetes to purchase up to three vials or two packs of FlexPen^®/FlexTouch^® pens of any combination of Novo Nordisk analog insulins (3000 – 3600 Units total depending on brands) for a flat cost of $99.00. Studies and clinical experience suggest that is an adequate supply to cover the monthly needs of most people with diabetes. This program is being made available from the Novo Nordisk US affiliate Novo Nordisk Inc. (NNI)

NovoLog^® and NovoLog^® Mix Follow-On Brands (also known as an authorized generic): Follow-on brand versions of NovoLog^® and NovoLog^® Mix will be made available from the newly established Novo Nordisk US affiliate Novo Nordisk Pharma Inc. (NNPI) The follow-on brands will be priced at a 50 percent discount compared to the current list price of the branded versions. NovoLog^® is Novo Nordisk's most widely prescribed insulin, used by approximately one million people with diabetes in the US.